Background: Deposition of crystals within tubular lumens is a feature of many kidney stone diseases, including crystals of calcium oxalate monohydrate (COM) in primary hyperoxaluria and of 2,8-dihydroxyadenine (DHA) in adenine phosphoribosyltransferase deficiency. Crystals are injurious to renal epithelial cells, but the molecular bases of cell injury have not been well characterized. Methods: We used a cDNA microarray to identify the time-dependent changes in gene expression associated with the interaction of COM or DHA crystals with primary cultures of normal human kidney cortical epithelial cells. Results: We observed gene expression changes that were common to both crystal types, as well as a number of crystal-specific responses. A subset of genes known to be aberrantly expressed in kidney tissue from stone formers also showed an altered expression in COM- or DHA-treated normal human kidney cortical epithelial cells. Conclusions: Our results show that cultured epithelial cells exposed to COM or DHA crystals demonstrate cellular responses that may be physiologically relevant, thus suggesting that this experimental system may be useful for elucidating the mechanisms of crystal-induced renal cell injury.

1.
Lieske JC, Spargo BH, Toback FG: Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type I primary hyperoxaluria. J Urol 1992;148:1517–1519.
2.
Gelb AB, Fye KH, Tischfield JA, Sahota AS, Sparks JW, Hancock DC, Sibley RK: Renal insufficiency secondary to 2,8-dihydroxyadenine urolithiasis. Hum Pathol 1992;23:1081–1085.
3.
Palacin M, Goodyer P, Nunes V, Gasparini P: Cystinuria; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, pp 4909–4932.
4.
Conger JD: Acute uric acid nephropathy. Med Clin North Am 1990;74:859–871.
5.
Chau H, El-Maadawy S, McKee MD, Tenenhouse HS: Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2. J Bone Miner Res 2003;18:644–657.
6.
Wang SS, Devuyst O, Courtoy PJ, Wang XT, Wang H, Wang Y, et al: Mice lacking renal chloride channel, CLC-5, are a model for Dent’s disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum Mol Genet 2000;9:2937–2945.
7.
Engle SJ, Stockelman MG, Chen J, Boivin G, Yum MN, Davies PM, et al: Adenine phosphoribosyltransferase-deficient mice develop 2,8-dihydroxyadenine nephrolithiasis. Proc Natl Acad Sci USA 1996;93:5307–5310.
8.
Redhead NJ, Selfridge J, Wu CL, Melton DW: Mice with adenine phosphoribosyltransferase deficiency develop fatal 2,8-dihydroxyadenine lithiasis. Hum Gene Ther 1996;7:1491–1502.
9.
Stockelman MG, Lorenz JN, Smith FN, Boivin GP, Sahota A, Tischfield JA, Stambrook PJ: Chronic renal failure in a mouse model of human adenine phosphoribosyltransferase deficiency. Am J Physiol 1998;275(1 Pt 2):F154–F163.
10.
Feliubadalo L, Arbones ML, Manas L, Chillaron J, Visa J, Rodes M, et al: Slc7a9-deficient mice develop cystinuria non-I and cystine urolithiasis. Hum Mol Genet 2003;12:2097–2108.
11.
Peters T, Thaete C, Wolf S, Popp A, Sedlmeier R, Grosse J, et al: A mouse model for cystinuria type 1. Hum Mol Genet 2003;12:2109–2120.
12.
Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C Jr, Jones P, et al: Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 1994;91:742–746.
13.
de Bruijn WC, Boeve ER, van Run PR, van Miert PP, Romijn JC, Verkoelen CF, et al: Etiology of experimental calcium oxalate monohydrate nephrolithiasis in rats. Scanning Microsc 1994;8:541–549.
14.
Evan AP, Bledsoe SB, Connors BA, Deng L, Liang L, Shao C, et al: Sequential analysis of kidney stone disease in the Aprt knockout mouse. Kidney Int 2001;60:910–923.
15.
Khan SR: Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol 2004;98:e55–e60.
16.
Khan SR, Thamilselvan S: Nephrolithiasis: a consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol Urol 2000;4:305–312.
17.
Asselman M, Verhulst A, De Broe ME, Verkoelen CF: Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 2003;14:3155–3166.
18.
Sorokina EA, Wesson JA, Kleinman JG: An acidic peptide sequence of nucleolin-related protein can mediate the attachment of calcium oxalate to renal tubular cells. J Am Soc Nephrol 2004;15:2057–2065.
19.
Verhulst A, Asselman M, Persy VP, Schepers MS, Helbert MF, Verkoelen CF, De Broe ME: Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding- into a non-adherent epithelium. J Am Soc Nephrol 2003;14:107–115.
20.
Verkoelen CF, Romijn JC, de Bruijn WC, Boeve ER, Cao LC, Schroder FH: Association of calcium oxalate monohydrate crystals with MDCK cells. Kidney Int 1995;48:129–138.
21.
Asselman M, Verkoelen CF: Crystal-cell interaction in the pathogenesis of kidney stone disease. Curr Opin Urol 2002;12:271–276.
22.
Bigelow MW, Wiessner JH, Kleinman JG, Mandel NS: Calcium oxalate crystal attachment to cultured kidney epithelial cell lines. J Urol 1998;160:1528–1532.
23.
Lieske JC, Hammes MS, Toback FG: Role of calcium oxalate monohydrate crystal interactions with renal epithelial cells in the pathogenesis of nephrolithiasis: a review. Scanning Microsc 1996;10:519–533.
24.
Lieske JC, Norris R, Toback GF: Adhesion of hydroxyapatite crystals to anionic sites on the surface of renal epithelial cells. Am J Physiol 1997;273(2 Pt 2):F224–F233.
25.
Koka RM, Huang E, Lieske JC: Adhesion of uric acid crystals to the surface of renal epithelial cells. Am J Physiol Renal Physiol 2000;278:F989–F998.
26.
Verkoelen CF, van der Boom BG, Houtsmuller AB, Schroder FH, Romijn JC: Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol 1998;274(5 Pt 2):F958–F965.
27.
Toback FG: Induction of growth in kidney epithelial cells in culture by Na+. Proc Natl Acad Sci USA 1980;77:6654–6656.
28.
Hammes MS, Lieske JC, Pawar S, Spargo BH, Toback FG: Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int 1995;48:501–509.
29.
Koul HK, Menon M, Chaturvedi LS, Koul S, Sekhon A, Bhandari A, Huang M: COM crystals activate the p38 mitogen-activated protein kinase signal transduction pathway in renal epithelial cells. J Biol Chem 2002;277:36845–36852.
30.
Sarica K, Erbagci A, Yagei F, Bakir K, Erturhan S, Ucak R: Limitation of apoptotic changes in renal tubular cell injury induced by hyperoxaluria. Urol Res 2004;32:271–277.
31.
Farell G, Huang E, Kim SY, Horstkorte R, Lieske JC: Modulation of proliferating renal epithelial cell affinity for calcium oxalate monohydrate crystals. J Am Soc Nephrol 2004;15:3052–3062.
32.
Khan SR, Kok DJ: Modulators of urinary stone formation. Front Biosci 2004;9:1450–1482.
33.
Kumar V, Yu S, Farell G, Toback FG, Lieske JC: Renal epithelial cells constitutively produce a protein that blocks adhesion of crystals to their surface. Am J Physiol Renal Physiol 2004;287:F373–F383.
34.
Ryall RL: Macromolecules and urolithiasis: parallels and paradoxes. Nephron Physiol 2004;98:37–42.
35.
Lieske JC, Deganello S, Toback FG: Cell-crystal interactions and kidney stone formation. Nephron 1999;81(Suppl 1):8–17.
36.
Wang L, Raikwar N, Yang M, Deng L, McAteer JA, Stambrook PJ, et al: Induction of α-catenin, integrin α3, integrin β6, and PDGF-B by 2,8-dihydroxyadenine crystals in cultured kidney epithelial cells. Exp Nephrol 2002;10:365–373.
37.
Kempson SA, McAteer JA, Al-Mahrouq HA, Dousa TP, Dougherty GS, Evan AP: Proximal tubule characteristics of cultured human renal cortex epithelium. J Lab Clin Med 1989;113:285–296.
38.
McAteer JA, Kempson SA, Evan AP: Culture of human renal cortex epithelial cells. J Tissue Cult Methods 1991;13:143–148.
39.
Lieske JC, Leonard R, Toback FG: Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific ions. Am J Physiol 1995;268(4 Pt 2):F604–F612.
40.
Vittal R, Selvanayagam ZE, Sun Y, Hong J, Liu F, Chin KV, Yang CS: Gene expression changes induced by green tea polyphenol (–)-epigallocatechin-3-gallate in human bronchial epithelial 21BES cells analyzed by DNA microarray. Mol Cancer Ther 2004;3:1091–1099.
41.
Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, et al: Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by microarray. Clin Cancer Res 2003;9:5486–5492.
42.
Zheng X, Ravatn R, Lin Y, Shih WC, Rabson A, Strair R, et al: Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis. Nucleic Acids Res 2002;30:4489–4499.
43.
Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863–14868.
44.
Roelofs JJ, Rowshani AT, van den Berg JG, Claessen N, Aten J, ten Berg IJ, et al: Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection. Kidney Int 2003;64:1845–1853.
45.
Figarella C, Amouric M, Guy-Crotte O: Pancreatic stone protein, protein X, and thread protein. Lancet 1987;1:222–223.
46.
Verdier JM, Dussol B, Casanova P, Daudon M, Dupuy P, Berthezène P, et al: Evidence that human kidney produces a protein similar to lithostathine, the pancreatic inhibitor of CaCO3 crystal growth. Eur J Clin Invest 1992;22:469–474.
47.
Hackett RL, Shevock PN, Khan SR: Alterations in MDCK and LLC-PK1 cells exposed to oxalate and calcium oxalate monohydrate crystals. Scanning Microsc 1995;9:587–596.
48.
Ellerby LM, Andrusiak RL, Wellington CL, Hackam AS, Propp SS, Wood JD, et al: Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 1999;274:8730–8736.
49.
Kaminker PG, Kim SH, Taylor RD, Zebarjadian Y, Funk WD, Morin GB, et al: TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression. J Biol Chem 2001;276:35891–35899.
50.
Du C, Guan Q, Yin Y, Zhong R, Jevnikar AM: IL-2 mediated apoptosis of kidney tubular cells is regulated by the caspase-8 inhibitor c-FLIP. Kidney Int 2005;67:1397–1409.
51.
Knoll T, Steidler A, Trojan L, Sagi S, Schaaf A, Yard B, et al: The influence of oxalate on renal epithelial and interstitial cells. Urol Res 2004;32:304–309.
52.
Lee JK: Analysis issues for gene expression array data. Clin Chem 2001;47:1350–1352.
53.
Chen DH, Kaung HL, Miller CM, Resnick MI, Marengo SR: Microarray analysis of changes in renal phenotype in the ethylene glycol rat model of urolithiaisis: potential and pitfalls. BJU Int 2004;94:637–650.
54.
Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, Terry PA, et al: Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR – how well do they correlate? BMC Genomics 2005;6:59.
55.
Rockett JC, Hellmann GM: Confirming microarray data – is it really necessary? Genomics 2004;83:541–549.
56.
Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC: Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res 2002;30:e48.
57.
Kohjimoto Y, Ebisuno S, Tamura M, Ohkawa T: Adhesion and endocytosis of calcium oxalate crystals on renal tubular cells. Scanning Microsc 1996;10:459–468.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.